Recent Updates
Recently added Catalysts
AMGN Positive Sentiment Score: 70/100

AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after...

Key Takeaway: Amgen has announced it will report its fourth quarter and full year 2023 financial results on February 6, 2024, followed by a conference call. The call will feature the CEO and other senior management members, providing an opportunity for the investment community to engage directly. The webcast will be available for all stakeholders and archived for future access. This event highlights Amgen's ongoing commitment to transparency and investor relations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Amgen is set to release its financial results, indicating ongoing business operations.
  • The conference call will provide insight directly from senior management, enhancing transparency.
  • Amgen's focus on high unmet medical needs showcases its commitment to innovative therapeutics.

Full Press Release Details

THOUSAND OAKS, Calif. , Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive officer, and other members of Amgen's senior management team.
Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME.
CONTACT: Amgen, Thousand Oaks Jessica Akopyan , 805-440-5721 (media) Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors)

21 %

Frequently Asked Questions

When will Amgen report its Q4 and full year 2023 results?

Amgen will report its results on February 6, 2024, after U.S. market close.

Who will participate in the Amgen conference call?

Robert A. Bradway and other senior management members will participate.

How can I listen to the Amgen conference call?

The conference call will be broadcast live online and is open to the public.

Where can I find Amgen's webcast archive?

Webcast archives will be available on Amgen's website for at least 90 days.

What is Amgen's main focus as a company?

Amgen aims to develop innovative therapeutics for serious illnesses.

Last updated: Feb 1, 2024